ライフサイエンスコーパス: CTGF

1 CTGF and integrin alphavbeta6 are potential therapeutic

2 CTGF and integrin alphavbeta6 proteins were highly expre

3 CTGF and integrin alphavbeta6 regulate oval cell activat

4 CTGF associated nominally with CKD (HR, 0.83; 95% CI, 0.

5 CTGF binds to the M6P/IGF-2-R with high affinity, and th

6 CTGF can affect EMD- and TGF-beta1-induced PDL cell prol

7 CTGF has been proposed to function as a critical TGF-bet

8 CTGF induces TM fibronectin and alpha-SMA in animals, wh

9 CTGF inhibition downregulated both EMD- and TGF-beta1-in

10 CTGF is a cytokine overexpressed in the intestine of pat

11 CTGF is cleaved in vivo into distinct domains.

12 CTGF KD MSCs differentiated into adipocytes at a sixfold

13 CTGF KD MSCs exhibited fivefold lower proliferation comp

14 CTGF levels were quantified by immunoblotting and ELISA.

15 CTGF overexpression, under nonstimulatory conditions, do

16 CTGF pretreatment of astrocytes increased their expressi

17 CTGF protein expression was evident by day 3 of AngII ex

18 CTGF silencing also decreased the expression of SPARC, p

19 CTGF SNPs do not influence the rate of recurrence after

20 CTGF treatment increases the number of immature beta-cel

21 CTGF treatment upregulates positive cell-cycle regulator

22 CTGF-induced changes in gene expression, actin cytoskele

23 CTGF-overexpressing mice provide a model that mimics the

24 CTGF/CCN2 stimulates retinal neovascularization through

25 teins including TGF-beta1, alpha-SMA, PAI-1, CTGF, FN and collagen-1.

26 Genotyping was performed for 4 CTGF SNPs (rs9402373, rs12526196, rs6918698, and rs93990

27 with thrombospondin repeat 7 (ADAMTS7) as a CTGF binding protein.

28 Overexpression of a CTGF plasmid lacking the 3'-UTR and administration of re

29 h factor-beta-induced collagen accumulation, CTGF, and PAI-1 expression, but enhances Smad7 protein e

30 in-1, collagen I, alpha-smooth muscle actin, CTGF, and PAI-1, but decreased Smad7 expression.

31 In addition, CTGF contributes to fibrocyte proliferation in the myoca

32 of blocking antibodies specifically against CTGF domain 4 or recombinant Dickkopf-related protein-1,

33 alphaSMA, EDA-fibronectin, collagen 1A, and CTGF.

34 don cells were stimulated with IL-1beta, and CTGF and significantly higher in CD146(+) TSCs than CD14

35 Aldosterone and CTGF increased lysyl oxidase, and aldosterone enhanced m

36 stream target genes, for example, ANKRD1 and CTGF.

37 ), which modulate nuclear factor binding and CTGF production, and a smad3 SNP (rs17293632) involved i

38 Additionally, (125)I-CTGF-binding and CTGF-stimulated proliferation were measured in cultures

39 TGF-beta1, COL1A1, and CTGF expression was inhibited by Stattic or dominant-neg

40 eading to increased TGF-beta1, collagen, and CTGF production in ileal strictures.

41 rtices from diabetic mice (both CTGF +/+ and CTGF +/-) manifested higher expression of CTGF and throm

42 glucose levels were increased in CTGF+/+ and CTGF+/- mice (28.2 3.3 mmol/L vs 27.0 3.1 mmol/L), plasm

43 ere similar between non-diabetic CTGF+/+ and CTGF+/- mice.

44 n-responsive genes including ATF3, CYR61 and CTGF, all of which have been implicated in human hypospa

45 ted with and without TGF-beta inhibitor, and CTGF protein levels were assayed by Western blot analysi

46 ation of bone morphogenic protein 4 mRNA and CTGF mRNA (inhibitors of OPC differentiation) and the do

47 The Smad2 phosphorylation and CTGF induction required signaling via both the TGFbeta-r

48 Both SCM and CTGF inhibited the differentiation of purified rat oligo

49 beta-regulated genes, including SERPINE1 and CTGF, declined (P = 0.049 and P = 0.012, respectively),

50 e in collagen I, fibronectin 1, TGFbeta, and CTGF mRNA in Ctr but not in betaRM hearts.

51 ocin-induced diabetes in wild type (+/+) and CTGF heterozygous (+/-) mice.

52 Anti-CTGF reversed the SCM-mediated effects on myelination.

53 Furthermore, treatment with BQ123 or an anti-CTGF antibody attenuated alpha-SMA expression induced by

54 FG-3019, an anti-CTGF monoclonal antibody, was used to inhibit CTGF.

55 fer the first preclinical validation of anti-CTGF therapy for the treatment of advanced melanoma and

56 Most importantly, the anti-CTGF antibody, FG-3019, had a profound inhibitory effect

57 erone, specifically RhoA activity as well as CTGF, lysyl oxidase, and microRNA-21 expression.

58 In the present study, we assessed CTGF expression in HCV-infected hepatocytes using replic

59 m signaling molecules, including c-myc, axl, CTGF, cyr61 and survivin and upregulation of the tumor g

60 Cortices from diabetic mice (both CTGF +/+ and CTGF +/-) manifested higher expression of C

61 entiation of CD146+ stem/progenitor cells by CTGF delivery successfully led to tendon regeneration wi

62 last cultures was significantly displaced by CTGF, but not by related growth factors.

63 CTGF expression in human BM-derived MSCs by CTGF short hairpin RNA.

64 the OC compartment, where its absence causes CTGF accumulation, leading to increased OC activation an

65 TEA domain-dependent transcription and CCN2/CTGF expression.

66 ity of connective tissue growth factor (CCN2/CTGF) to C-terminal cystine knot motifs present in key a

67 rowth factor-beta-induced expression of CCN2/CTGF and periostin.

68 al analysis showed close association of CCN2/CTGF with these regulators in murine angiogenesis models

69 YAP target gene (CCNE1, CTGF, Cyr61) mRNA expression was also increased in the t

70 Clinically, CTGF expression correlates with tumor progression and is

71 After being cultured, CTGF was increased in fibrocytes from patients with COA,

72 CYR61-CTGF-NOV (CCN)1 is a dynamically expressed extracellular

73 1, a matricellular protein of the CCN (CYR61/CTGF/NOV) family, is accumulated in hepatocytes of human

74 eted matricellular protein of the CCN (CYR61/CTGF/NOV) family, is significantly downregulated in clin

75 adenoviral system in vitro led to decreased CTGF expression and reduced proliferation and Transwell

76 cific knockdown of Smad3 partially decreases CTGF production, whereas it has no significant influence

77 by connective tissue growth factor delivery (CTGF delivery) in the early phase of tendon healing, fol

78 In vitro characterization demonstrated CTGF binding and processing by ADAMTS7.

79 activities of LPA by driving MRTF-dependent CTGF expression, which, in turn, drives fibroblast proli

80 th (PICP, ICTP, MMP-2, TGF-beta1, desmosine, CTGF, TIMP-1).

81 highlight the potential value of developing CTGF-based anti-fibrotic therapies to counter HCV-induce

82 Plasma creatinine was higher in diabetic CTGF+/+ group (11.7+/-1.2 vs 7.9+/-0.6 micromol/L p<0.01

83 mesangial expansion were reduced in diabetic CTGF+/- animals.

84 rol levels were similar between non-diabetic CTGF+/+ and CTGF+/- mice.

85 f MRTF-induced transcription also diminished CTGF expression and fibrosis in the peritoneal fibrosis

86 Early CTGF expression occurred before fibrocyte migration (1 d

87 ered in the scaffolds by spatially embedding CTGF- or TGFbeta3-encapsulated microspheres (microS) to

88 We discovered that in embryos CTGF is necessary for beta-cell proliferation, and incre

89 The results provide novel insights into EMD-CTGF interaction in PDL cells.

90 YAP and TAZ connective tissue growth factor (CTGF) and Cyr61 target genes, and exhibit anchorage-inde

91 Connective tissue growth factor (CTGF) and transforming growth factor beta 3 (TGFbeta3) w

92 nsisting of connective tissue growth factor (CTGF) and vascular endothelial growth factor (VEGF).

93 identified connective tissue growth factor (CTGF) as a novel target of miR-145 in glioma cells; tran

94 , we define connective tissue growth factor (CTGF) as a therapeutic target for metastatic melanoma.

95 alpha1, and connective tissue growth factor (CTGF) gene expression was measured by quantitative RT-PC

96 one induced connective tissue growth factor (CTGF) in the absence but not in the presence of cortisol

97 Delivery of connective tissue growth factor (CTGF) into full-transected rat patellar tendons signific

98 Connective tissue growth factor (CTGF) is a downstream mediator of TGF-beta.

99 Connective tissue growth factor (CTGF) is a fibrogenic cytokine that is up-regulated by T

100 Connective tissue growth factor (CTGF) is a key mediator of tissue fibrogenesis in kidney

101 Connective tissue growth factor (CTGF) is a matricellular protein that mediates cell-matr

102 Connective tissue growth factor (CTGF) is a multifunctional secreted protein that acts as

103 Connective tissue growth factor (CTGF) is a TGF-beta2 target gene with high constitutive

104 Connective tissue growth factor (CTGF) is an important mediator of fibrosis; emerging evi

105 otic liver, connective tissue growth factor (CTGF) is constantly expressed in activated hepatic stell

106 In mice, connective tissue growth factor (CTGF) is expressed in embryonic beta-cells and in adult

107 Connective tissue growth factor (CTGF) is highly expressed in MSCs, but its role in the B

108 Connective tissue growth factor (CTGF) is important for OC activation and contributes to

109 Connective tissue growth factor (CTGF) is known to regulate fibroblast activities.

110 ted protein connective tissue growth factor (CTGF) is upregulated in response to cardiac injury or wi

111 ic cytokine connective tissue growth factor (CTGF) plays an important role in the development and pro

112 . show that connective tissue growth factor (CTGF) regulates a multicellular signaling cascade determ

113 protein for connective tissue growth factor (CTGF) than OECs.

114 Connective tissue growth factor (CTGF) up-regulation induced by aldosterone was prevented

115 in POH, and connective tissue growth factor (CTGF) was overexpressed in all types of LVH.

116 Connective tissue growth factor (CTGF), a direct target of miR-133b, is crucial in the du

117 identified connective tissue growth factor (CTGF), a matricellular protein that is highly expressed

118 Connective tissue growth factor (CTGF), a matrix-associated protein with four distinct cy

119 synthesis, connective tissue growth factor (CTGF), and alpha-smooth muscle actin gene expression at

120 61 (CYR61), connective tissue growth factor (CTGF), and ankyrin repeat domain 1 (ANKRD1).

121 scle actin, connective tissue growth factor (CTGF), and plasminogen activator inhibitor (PAI-1).

122 target CCN2/connective-tissue growth factor (CTGF), as well as anchorage-independent growth, capacity

123 to express connective tissue growth factor (CTGF), driving fibroblast proliferation in a paracrine f

124 GF-betaR1), connective tissue growth factor (CTGF), E-cadherin, SRY-box 7 (SOX7), and NFAT (nuclear f

125 , including connective tissue growth factor (CTGF), fibronectin, and collagens Col1a1, Col3a1, Col6a3

126 TGF-beta1), connective tissue growth factor (CTGF), procollagen I carboxy-terminal propeptide (PICP),

127 oduction of connective tissue growth factor (CTGF).

128 ecretion of connective tissue growth factor (CTGF).

129 yclin A and connective tissue growth factor (CTGF).

130 so known as connective tissue growth factor (CTGF)], markers of epithelial to mesenchymal transition,

131 1/2 acts on connective tissue growth factor (CTGF/CCN2) expression to mediate the myocardial fibrosis

132 The role of connective tissue growth factor (CTGF/CCN2) in pathological angiogenesis in the retina is

133 Myocardial connective tissue growth factor (CTGF/CCN2) is induced in heart failure, a condition asso

134 dicate that connective tissue growth factor (CTGF/CCN2) stimulates chondrocyte proliferation and matu

135 tricellular connective tissue growth factor (CTGF/CCN2).

136 ing protein connective tissue growth factor (CTGF/CCN2).

137 s suggest that ADAMTS7 is a new protease for CTGF protein and a novel regulator in the OC compartment

138 ffinity, and the M6P/IGF-2-R is required for CTGF-stimulated proliferation in fibroblasts.

139 Our studies demonstrate a central role for CTGF expression in HCV-induced liver fibrosis and highli

140 irst time that the ETAR pathway is vital for CTGF expression, which results in fibrocyte differentiat

141 In cultured MEF from CTGF+/+ mice, glucose (25 mM) increased expression of pr

142 anscriptional activation of its target gene, CTGF.

143 ad and neck squamous cell carcinoma (HNSCC), CTGF promotes the MET and reduces invasiveness.

144 However, CTGF mildly altered the overall cardiac response to TGF-

145 fa overexpression or local delivery of human CTGF recombinant protein accelerated bridging and functi

146 iomyocytes pretreated with recombinant human CTGF (rec-hCTGF) revealed marked reduction of both beta(

147 tment of whole islets with recombinant human CTGF induces beta-cell replication and gene expression c

148 and fibrocytes expressing CD45, collagen I, CTGF, ETAR, or alpha-SMA were identified by flow cytomet

149 Binding of (125)I-CTGF to fibroblast cultures was significantly displaced

150 0 kDa complex containing cross-linked (125)I-CTGF was immunoprecipitated by antibodies to CTGF or M6P

151 Additionally, (125)I-CTGF-binding and CTGF-stimulated proliferation were meas

152 We therefore examined if CTGF inhibition has anti-fibrotic effects in PF.

153 /+ animals; this reduction was attenuated in CTGF+/- group.

154 hese genes by high glucose was attenuated in CTGF+/- MEF.

155 6 expression was significantly attenuated in CTGF-delivered tendon healing.

156 n intervertebral disc led to the decrease in CTGF expression.

157 Leptin was found to be highly expressed in CTGF KD EXM-BM and in BM samples of patients with acute

158 trix metalloproteinase (MMP)-3 expression in CTGF-delivered tendon was organized along with the reori

159 Corroborating a mechanism of GRK5 in CTGF-mediated control of beta-AR sensitivity, Chinese ha

160 ific Tsc1 deletion results in an increase in CTGF secretion that non-cell autonomously stunts oligode

161 ate, plasma glucose levels were increased in CTGF+/+ and CTGF+/- mice (28.2 3.3 mmol/L vs 27.0 3.1 mm

162 L), plasma triglyceride levels were lower in CTGF+/- mice than in CTGF+/+ (0.7 0.2 mmol/L vs 0.5 0.1

163 Expression of nephrin was reduced in CTGF +/+ animals; this reduction was attenuated in CTGF+

164 de levels were lower in CTGF+/- mice than in CTGF+/+ (0.7 0.2 mmol/L vs 0.5 0.1 mmol/L, p<0.05), but

165 Thus, genetic variability in CTGF expression directly modulates the severity of diabe

166 y for beta-cell proliferation, and increased CTGF in beta-cells promotes proliferation of immature (M

167 e, whereas the RhoA activator CN03 increased CTGF expression.

168 lial cells responded to AngII with increased CTGF production (2.1-fold and 2.8-fold, respectively; P

169 HSD2 siRNA abolished the aldosterone-induced CTGF up-regulation.

170 Activation of mesothelial cell LPA1 induced CTGF expression by inducing cytoskeleton reorganization

171 tin is induced by angiotensin II and induces CTGF in cardiomyocytes.

172 TGF monoclonal antibody, was used to inhibit CTGF.

173 Studies in vivo demonstrate that inhibiting CTGF/CCN2 using a specific antibody decreases myocardial

174 R responsiveness in cardiomyocytes involving CTGF-mediated regulation of GRK5.

175 Therefore, we knocked down (KD) CTGF expression in human BM-derived MSCs by CTGF short h

176 ted by TGF-beta contained full length 38-kDa CTGF and fragments of 25, 21, 18, and 13 kDa, while cond

177 Proteolytic processing of 38-kDa CTGF occurs during corneal wound healing, which may have

178 21-kDa fragments and trace amounts of 38-kDa CTGF, although no alternative transcripts were detected.

179 5) downstream signaling molecule to mediate CTGF expression.

180 induces matrix metalloproteinase-3-mediated CTGF cleavage, resulting in VEGF release and MSC endothe

181 nvolvement of Stat3 activation in modulating CTGF production upon TGF-beta challenge in activated HSC

182 c minipumps (2.0 mug/kg per min), myocardial CTGF mRNA peaked at 6 hours (21-fold; P < 0.01), whereas

183 so, neither heart-specific Ctgf deletion nor CTGF overexpression altered cardiac remodeling and funct

184 l obstruction in vivo Therefore, domain 4 of CTGF and the WNT signaling pathway are important new tar

185 In this study, we tested the ability of CTGF to promote beta-cell proliferation and regeneration

186 signaling, leading to altered activation of CTGF/CCN2 to mediate fibrosis and alter cardiac function

187 Addition of CTGF increased levels of phosphorylation of five phospho

188 Coexpression of CTGF and the pluripotency genes was found to be associat

189 Genetic deletion of CTGF from neurons, in turn, mitigates the TSC-dependent

190 Depletion of CTGF by RNA interference leads to a marked attenuation o

191 High dose of CTGF/TGFbeta3-microS (100 mg microS/g of scaffold) showe

192 viscosity was achieved with the high dose of CTGF/TGFbeta3-microS compared with the low-dose and empt

193 Similarly, a high dose of CTGF/TGFbeta3-microS yielded significantly higher collag

194 we showed that shRNA-mediated knock-down of CTGF resulted in reduced expression of fibrotic markers

195 The effect of CTGF and EMD on osteoblastic mRNA expression in PDL cell

196 empty microS, suggesting the dose effect of CTGF and TGFbeta3 on fibrocartilage formation.

197 To study the effect of CTGF on engraftment of leukemia cells into BM, an in viv

198 The effect of CTGF on isolated fibrocytes suggested a role in fibrocyt

199 of SPARC abrogated the inhibitory effect of CTGF silencing on cell migration.

200 new gene targets and downstream effectors of CTGF/CCN2 and provided the rational basis for targeting

201 ng the p53 pathway to curtail the effects of CTGF/CCN2 on neovessel formation associated with ischemi

202 Concordantly, the neovascular effects of CTGF/CCN2 were suppressed by p53 inhibition that culmina

203 ntagonist (BQ788), reduced the expression of CTGF and alpha-SMA in fibrocytes and fibrocyte different

204 nd CTGF +/-) manifested higher expression of CTGF and thrombospondin 1 (TSP1).

205 with this miRNA decreased the expression of CTGF as determined by Western blot analysis and the expr

206 ties in TM cells, and that the expression of CTGF is regulated closely by Rho GTPase.

207 significantly up-regulated the expression of CTGF, a potent profibrotic cytokine.

208 of astrocytes increased their expression of CTGF, suggesting that this inhibitory factor can be posi

209 ned full length 38- and a 21-kDa fragment of CTGF that contained the middle "hinge" region of CTGF.

210 nduced a concentration-dependent increase of CTGF protein expression in PDL cells.

211 The induction of CTGF by PAR2-AP was synergistically increased when combi

212 hese findings suggest that the inhibition of CTGF by FG-3019 might be a novel treatment for PF throug

213 Mechanistically, inhibition of CTGF decreased invasion and migration associated with re

214 Genetic inhibition of CTGF in human melanoma cells is sufficient to significan

215 Knockdown of CTGF in TW2.6 cells was shown to reduce tumor formation

216 lower for infants with detectable levels of CTGF than for those with CTGF levels below the level of

217 Remarkably, neither gain nor loss of CTGF in the heart affected cardiac pathology and propens

218 a1 (TGF-beta1) as a key upstream mediator of CTGF production using neutralizing antibodies and shRNAs

219 on showed rapid increases within 1 minute of CTGF exposure that peaked between 5 and 10 minutes then

220 fibrosis was also unchanged by modulation of CTGF levels in the heart with aging, pressure overload,

221 ce with cardiac-restricted overexpression of CTGF (Tg-CTGF) or cardiomyocytes pretreated with recombi

222 tissue-specific inducible overexpression of CTGF by kidney pericytes and fibroblasts had no bearing

223 tes in bronchial walls and overexpression of CTGF in fibrocytes from patients with COA.

224 and hyperproliferative on overexpression of CTGF.

225 st resulted in Smad2-dependent production of CTGF by resident cells (6 hours), well before the accumu

226 that contained the middle "hinge" region of CTGF.

227 cardiac fibroblasts and the up-regulation of CTGF and fibronectin.

228 collidine in mice, led to down-regulation of CTGF expression and OC proliferation.

229 e investigate whether miR-133b regulation of CTGF influences HCC cell proliferation and migration, an

230 ese results show that miR-133b regulation of CTGF is a novel mechanism critical for the proliferation

231 This study investigated the role of CTGF and integrin alphavbeta6 in hepatic progenitor/oval

232 Here, we investigated the role of CTGF in fibrogenic cells.

233 cells, the data suggest an important role of CTGF in MSC differentiation into adipocytes and of lepti

234 To study the role of CTGF in PDL development, cells were treated with CTGF in

235 present study, we characterized the role of CTGF in promoting fibrocyte accumulation and regulation

236 To further ascertain the role of CTGF in responses to high glucose, we assessed the conse

237 findings suggest anti-inflammatory roles of CTGF-stimulated TSCs that are likely associated with imp

238 Similarly, we found that silencing of CTGF decreased the migration of glioma cells.

239 Significantly, an exogenous source of CTGF was able to rescue the cell proliferation defect in

240 and cholangiocytes were the main sources of CTGF and integrin alphavbeta6 during liver injury induce

241 l mass reaches 50% recovery after 4 weeks of CTGF treatment, primarily via increased beta-cell prolif

242 ition of Ras, MEK1/2 (MAPKK), and ERK1/2, on CTGF-stimulated fibroblast proliferation and collagen ge

243 explore the effects of EMD and TGF-beta1 on CTGF expression, cells were treated with and without TGF

244 explores the effects of EMD and TGF-beta1 on CTGF in periodontal ligament (PDL) fibroblasts and their

245 was detected only when treated with CTGF or CTGF and IL-1beta that is significantly higher in CD146(

246 In parallel, CTGF delivery significantly reduced the number of iNOS(+

247 Levels of peritoneal CTGF expression were increased by CG challenges, and sup

248 Rho kinase inhibition by Y-27632 prevented CTGF and hydroxyproline, whereas the RhoA activator CN03

249 immunoprecipitation assays with radiolabeled CTGF and soluble mannose 6-phosphate/insulin-like growth

250 the 3'-UTR and administration of recombinant CTGF protein abrogated the inhibitory effect of miR-145

251 apamycin (mTOR) pathway in neurons regulates CTGF production and secretion, revealing a paracrine mec

252 t the FAK/ERK1/2 signaling pathway regulates CTGF-induced proliferation and differentiation of CD146+

253 mad signaling plays major role in regulating CTGF production, TGF-beta stimulated CTGF expression in

254 at a threefold higher rate in adipocyte-rich CTGF KD MSC-derived EXM-BM than in control EXM-BM.

255 In HNSCC patient samples, CTGF expression was positively correlated with the level

256 ransgenic mice with inducible heart-specific CTGF overexpression, mice with heart-specific expression

257 ulating CTGF production, TGF-beta stimulated CTGF expression in activated HSCs is only in part depend

258 EMD- and TGF-beta1-stimulated CTGF expression was significantly reduced in the presenc

259 EMD stimulates CTGF expression in human PDL cells, a process modulated

260 regulates glioma cell migration by targeting CTGF which downregulates SPARC expression.

261 ardiac-restricted overexpression of CTGF (Tg-CTGF) or cardiomyocytes pretreated with recombinant huma

262 Finally, Tg-CTGF mice subjected to chronic exposure (14 days) to iso

263 e upregulated in both cardiomyocytes from Tg-CTGF mice and cardiomyocytes exposed to rec-hCTGF.

264 ropic responses of myocardial fibers from Tg-CTGF mice and nontransgenic littermate control (NLC) mic

265 sistently, ventricular muscle strips from Tg-CTGF mice stimulated with isoproterenol displayed attenu

266 tion is mediated by a FOXO1 induced TGFbeta1/CTGF axis.

267 and Western blot analysis demonstrated that CTGF-induced expression of IL-10 and TIMP-3 in CD146(+)

268 h those observed in vivo, demonstrating that CTGF acts directly on islets to promote beta-cell replic

269 Moreover, we found that CTGF enhances the stem-like properties of HNSCC cells an

270 We also found that CTGF regulates its own expression via TGF-beta signaling

271 These data revealed that CTGF influences ECM synthesis, actin cytoskeletal dynami

272 on of the molecular mechanisms revealed that CTGF production was mediated through sequential activati

273 Our study reveals that CTGF is necessary and sufficient to stimulate glial brid

274 itoneal mesothelial cells (PMCs) showed that CTGF blockade suppressed TGF-beta1-induced fibroblast pr

275 Mechanistic studies showed that CTGF induces c-Jun expression through alphavbeta3 integr

276 the body, although our results suggest that CTGF is of minimal importance and is an unlikely therape

277 Collectively, our data suggest that CTGF regulates proliferation as a mediator of the canoni

278 and a smad3 SNP (rs17293632) involved in the CTGF pathway.

279 agonists reduced the aldosterone but not the CTGF effect.

280 Thus, CTGF can induce replication of adult mouse beta-cells gi

281 kinases are available to respond acutely to CTGF exposure.

282 bind to CTGF mediating oval cell adhesion to CTGF and fibronection substrata and promoting transformi

283 CTGF was immunoprecipitated by antibodies to CTGF or M6P/IGF-2-R.

284 Finally, integrin alphavbeta6 could bind to CTGF mediating oval cell adhesion to CTGF and fibronecti

285 asured at nine time points after exposure to CTGF using Western immunoblots.

286 The total CTGF production induced by TGF-beta in activated HSCs is

287 hat either adenoviral-mediated or transgenic CTGF overexpression in the mouse eye increases IOP and l

288 evidence link changes in plasma and urinary CTGF levels to diabetic kidney disease.

289 vely studied the association between urinary CTGF (CTGFu) levels and renal allograft fibrosis during

290 Finally, to determine whether CTGF regulates fibrosis, we showed that shRNA-mediated k

291 Accordingly, we aimed to investigate whether CTGF could play a mechanistic role in regulation of beta

292 Stimulation of HTM cells with CTGF for 24 hours induced actin stress fiber formation,

293 ctor 2 receptor (M6P/IGF-2-R) alone, or with CTGF-related growth factors were conducted.

294 s (MSCs) for 6 wk, 3D-printed scaffolds with CTGF/TGFbeta3-microS resulted in a heterogeneous fibroca

295 neous modulus was significantly smaller with CTGF/TGFbeta3-microS than empty microS.

296 etectable levels of CTGF than for those with CTGF levels below the level of detection.

297 in PDL development, cells were treated with CTGF inhibitor.

298 pression was detected only when treated with CTGF or CTGF and IL-1beta that is significantly higher i

299 at 0, 5, and 15 minutes after treatment with CTGF.

300 was expressed in CD146(+) TSCs at 1 wk with CTGF, in contrast to control with no TIMP-3 expression.